"AI has the potential to transform cancer care, but its progress has been held back by fragmented and inaccessible data," said Professor Anita Grigoriadis, CEO of PharosAI and Professor of Molecular and Digital Pathology at King's College London. "PharosAI changes that - creating rich, multimodal datasets and pairing them with cutting-edge AI models and analytical tools, powered by 10x Genomics' advanced spatial technologies to enable earlier diagnoses, more targeted therapies and better outcomes for patien ...

PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Thursday, February 12, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release ...

Industry Overview - The Medical Info Systems industry is rapidly expanding due to innovations in healthcare resource management, patient data handling, and integrated digital care delivery [1] - Companies in this industry develop and market healthcare information systems, providing software and hardware solutions for secure access to real-time clinical, administrative, and financial data [4] Market Growth and Trends - The use of artificial intelligence (AI) in healthcare is projected to grow at a CAGR of 38.6% from 2025 to 2030, driven by demand for enhanced diagnostic accuracy and personalized medicine [2] - The global Smart Healthcare Products market was valued at $280.48 billion in 2024 and is expected to reach $796.36 billion by 2032, growing at a CAGR of 15.37% [5] - Remote patient monitoring and telehealth services are experiencing significant growth due to increased awareness of continuous patient monitoring devices [5] Key Players - Doximity (DOCS) is a market leader in physician engagement, covering over 80% of U.S. doctors, with a subscription-based revenue model and a total addressable market of $18.55 billion [17] - 10x Genomics (TXG) develops products for analyzing biological systems, with a Zacks Consensus Estimate indicating a 72.4% improvement in earnings from 2024 to 2025 [21][22] - Omnicell (OMCL) focuses on medication management solutions and is expected to achieve a revenue CAGR of 2.8% from 2025 to 2027 [25] Financial Performance - The Medical Info Systems industry has underperformed the S&P 500 and the Zacks Medical sector, losing 7.7% over the past year compared to the sector's growth of 24.7% [11] - The industry is currently trading at a forward price-to-sales (P/S) ratio of 4.65X, lower than the S&P 500's 5.65X and the sector's 2.35X [14] Cybersecurity Concerns - As healthcare systems become more digital, cybersecurity has emerged as a critical concern, with rising instances of ransomware and cyberattacks targeting healthcare organizations [7][8]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Company Performance - 10x Genomics announced preliminary Q4 and full year 2025 results, reporting approximately $599 million in revenue for the full year and $166 million in Q4, exceeding the high end of their Q4 guidance [2] - The company generated about $40 million in cash, bringing its balance sheet to over $0.5 billion [2] Management Commentary - The CEO expressed pride in the team's performance amidst significant upheavals in various end markets, highlighting strong execution throughout the year [3] - The company experienced positive momentum in key metrics driving business fundamentals, multiple new product launches, and a strengthened balance sheet, positioning the company in its strongest state ever [3]

Summary of 10X Genomics FY Conference Call Company Overview - **Company**: 10X Genomics (NasdaqGS:TXG) - **Event**: FY Conference on January 12, 2026 - **Revenue**: $599 million for FY 2025, $166 million for Q4 2025, exceeding guidance [3][38] Core Industry Insights - **Industry**: Life Sciences Tools and Diagnostics - **Market Position**: 10X Genomics is positioned as a leader in single-cell analysis and spatial biology, emphasizing the importance of understanding biology at the cellular level [4][9][12] Key Points and Arguments 1. **Financial Performance**: - Achieved $599 million in total revenue for FY 2025, with a strong Q4 performance of $166 million [3] - Generated $40 million in cash, strengthening the balance sheet to over $500 million [3] 2. **Innovation and Product Development**: - Focus on building technologies to measure complex biological interactions at scale and resolution [5][6] - Launched multiple new products, including the Flex assay, which has become the most popular assay by volume [14][39] - Emphasis on single-cell and spatial analysis technologies, which are foundational for understanding health and disease [11][17] 3. **Market Trends**: - Increased interest in single-cell analysis driven by new applications and AI projects [13] - Spatial analysis technologies (Visium and Xenium) are gaining traction, with customers expressing high satisfaction [16][49] 4. **Customer Engagement**: - Strong customer momentum observed, particularly in the uptake of new products [39] - Positive feedback from customers regarding the performance and utility of products [10][54] 5. **Challenges and Opportunities**: - The capital equipment market remains challenging, with tightening budgets impacting instrument sales [40][46] - Despite challenges, there is optimism about future growth driven by translational research and diagnostics applications [27][30] 6. **AI Integration**: - AI is seen as a transformative force in biology, with potential to drive demand for data generation and analysis [19][55] - Collaboration with Anthropic aims to leverage AI for data analysis, addressing bottlenecks in bioinformatics [56] 7. **Translational Research**: - Increasing adoption of products in translational research, particularly in oncology and autoimmune diseases [27][32] - Partnerships with leading medical institutions to generate clinical evidence and develop diagnostic applications [35][31] 8. **Future Outlook**: - Plans to establish a CLIA lab to facilitate clinical deployment of diagnostic tests [31] - Anticipation of significant growth in diagnostics applications, particularly in precision medicine [30][34] Additional Important Insights - **Publications and Impact**: Over 10,000 papers published using 10X products, indicating widespread adoption and impact in various fields of biology [11] - **Customer Support**: Strong customer support and satisfaction metrics, with high Net Promoter Scores (NPS) [10] - **Acquisition of Scale Biosciences**: Expected to enhance capabilities in scaling experiments, though financial impact is minimal at this stage [58] Conclusion 10X Genomics is well-positioned in the life sciences industry, with a strong focus on innovation, customer engagement, and the integration of AI technologies. The company is navigating challenges in the capital equipment market while capitalizing on growth opportunities in translational research and diagnostics.

Financial Performance - Preliminary full-year 2025 revenue is approximately $599 million, excluding $44 million related to patent litigation settlements[5,6] - Q4 2025 revenue is approximately $166 million[6] - The company's cash balance grew by over $100 million compared to year-end 2024[7] Product and Market Leadership - 10x Genomics has launched over 35 major products in the last 10 years[16] - The company has over 2,700 patents and applications[16] - Over 6,400 Chromium instruments have been sold cumulatively[34] - Over 1,500 spatial instruments have been sold cumulatively[38] Technological Advancements and Partnerships - Chromium consumables reactions growth of more than 20%[7] - Spatial Consumables revenue growth of 19%[7] - The company is building an AI-ready immuno-oncology data engine powered by 10x, generating high-resolution molecular data from over 20,000 samples and profiling over 500 million cells[52] Translational Research and Future Applications - The company is collaborating to build the world's largest single-cell dataset derived from a single cohort of >1,000 immunotherapy patients[61] - Spatial multiomics data from ~7,000 patients to ID new disease biology, patient subtypes, biomarkers, and drug types[60]

Core Insights - The study conducted by 10x Genomics, Inc. aims to identify single cell immune signatures that correlate with disease activity and treatment response, which is intended to enhance clinical care [1] Group 1 - The research focuses on understanding immune responses at a single-cell level, which could lead to more personalized treatment strategies [1] - The findings are expected to support clinical decision-making by providing insights into how patients respond to various treatments [1] - The study highlights the importance of immune profiling in managing diseases, potentially improving patient outcomes [1]

Core Insights - 10x Genomics has announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types, aiming to uncover biological features linked to treatment response and disease progression [1][2] - The collaboration will utilize 10x's Chromium Flex single cell assay and Xenium spatial platform to create detailed molecular maps of tumors, integrating cellular composition and spatial architecture [3] - A CLIA-certified laboratory will be established by 10x to support the development of innovative diagnostic tests and provide the necessary infrastructure for assay implementation and clinical sample processing [4][5] Research Initiative - The study will evaluate samples from hundreds of patients to identify therapeutic targets and tumor microenvironment features relevant to emerging oncology therapies, including antibody-drug conjugates and immune checkpoint inhibitors [2] - The research aims to understand the variability in patient responses to treatments, potentially leading to optimized therapy strategies for clinicians [2][3] Technological Integration - The collaboration seeks to define actionable biomarkers for clinical reporting, focusing on insights from spatial and single cell analysis that could aid oncologists in treatment decision-making [3][4] - The integration of high-resolution tumor profiling with clinical outcomes is expected to generate insights that inform future clinical applications in precision oncology [4] Future Directions - This partnership marks the beginning of a multi-year research effort, with plans for additional studies and collaborations to develop the clinical potential of single cell and spatial technologies [5] - The goal is to enhance patient care by translating deep biological insights into improved clinical outcomes [5]

Core Insights - 10x Genomics, in collaboration with the Cancer Research Institute (CRI), is launching a multi-phase initiative to generate high-resolution molecular data from over 20,000 samples to enhance immuno-oncology research and develop new immunotherapies and vaccines [1][4]. Group 1: Project Overview - The initiative will start with a pilot phase involving leading researchers from top immuno-oncology laboratories, aiming to generate approximately 3,000 samples using 10x's Chromium and Xenium platforms [2]. - The full project phase will expand to a broader network of laboratories, utilizing 10x's Chromium Flex single cell assay to profile over 500 million cells [3]. Group 2: Objectives and Impact - The integrated dataset will help uncover mechanisms of immune response and resistance, refine existing treatments, and identify new therapeutic strategies, ultimately contributing to vaccine discovery [4]. - This collaboration aims to create a high-resolution immune atlas that can redefine cancer prevention and treatment strategies [5]. Group 3: Company Background - 10x Genomics is a life science technology company focused on advancing human health through products that enable researchers to understand biological systems at a high resolution and scale [7]. - The Cancer Research Institute, established in 1953, is dedicated to advancing immunotherapy research and has invested over $560 million in related studies [9].